EU/3/18/2004

About

On 21 March 2018, orphan designation (EU/3/18/2004) was granted by the European Commission to Quintiles Ireland Limited, Ireland, for tazemetostat for the treatment of diffuse large B-cell lymphoma.

In May 2018, Quintiles Ireland Limited changed name to IQVIA RDS Ireland Limited.

The sponsorship was transferred to Voisin Consulting S.A.R.L., France, in June 2019.

Key facts

Active substance
Tazemetostat
Disease / condition
Treatment of diffuse large B-cell lymphoma
Date of first decision
21/03/2018
Outcome
Positive
EU designation number
EU/3/18/2004

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

64 Avenue Pierre Grenier
92100 Boulogne Billancourt
France
Tel. + 33 (0)2 23 25 07 68
E-mail: brielle@voisinconsulting.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating